High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)

Inclusion Criteria: * Male or female caucasian patients ≥ 18 years of age * Diagnosis of high myopia secondary to an anterior-posterior elongation of the bulbus confirmed by ocular examination in either eye using the following criteria: * Ocular ultrasonography or biometry demonstrating anterior-posterior elongation measurement ≥ 26 mm * abnormal change in retinal tissue by SD-OCT that are attributed to be caused by high myopia as shown in Table 4-2 of the protocol in the investigator's discretion confirmed by the reading centre Exclusion Criteria: * Patients with Diabetes mellitus of any grade * Patients showing signs of Age-Related Macular Degeneration (AMD), e.g. drusen, characteristic changes in fundus (with shaping or extension of hemorrhages, fibrosis, exudative areas) in either eye * Acute neovascularization (CNV or iris neovascularization) and intra- or subretinal fluid in either eye at the time of enrolment. * History of inactive CNV in study eye. Inactive CNV of fellow eye is allowed if treatment was performed more than 12 months before enrolment. * Any anti vascular endothelial growth factor' (anti-VEGF) or Verteporfin treatment in study eye and anti-VEGF or Verteporfin treatment less than 12 months before enrolment in fellow eye * History of systemic anti vascular endothelial growth factor' (anti-VEGF) therapy * Cataract that would prevent an accurate measurement of the axial length of the study eye Other protocol-defined inclusion/exclusion criteria may apply